Doc, in today's world, a test like Onko Sure just does not offer enough. Twenty years ago, there were a lot of medical professionals thinking a pan cancer marker would have utility. It just did not work out. The huge problem with all the pan cancer markers out there are false positives.
From what I have researched, there are better ones than Onko Sure. Onko Sure has a lot of problems Radient excluded when they did the specificity testing. That's not right.
For a screen, you have to have near 100% specificity and very high sensitivity or you spend a ton of money on additional testing going nowhere and leading to a lot more false positives.
IMO, one of the biggest frauds the company played on investors was the "new generation" test. It turned out that no studies of a new test were even done. I will guarantee you one thing for sure. If the new antibody would have actually made a difference in the performance of the test, THAT would have been the focus of the studies.
Remember the conference call last year? The CEO said the new test performed the same as the old one and he admeitted that the test should not be used for general screening. That is what the caller got him to admit.
News 
Market Data 
Discover 
